Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Dothiepin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 known ✓ | P23975 | 5/20 | 0.97 |
| ▸ | SLC6A4 known ✓ | P31645 | 4/20 | 0.97 |
| ▸ | HRH1 | P35367 | 6/20 | 0.97 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.97 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.97 |
| ▸ | HTR2B | P41595 | 4/20 | 0.97 |
| ▸ | CHRM2 | P08172 | 4/20 | 0.97 |
| ▸ | ADRA2A | P08913 | 4/20 | 0.97 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.97 |
| ▸ | DRD2 | P14416 | 4/20 | 0.97 |
| ▸ | ADRA1A | P35348 | 4/20 | 0.97 |
| ▸ | DRD3 | P35462 | 4/20 | 0.97 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.97 |
| ▸ | ADRA2B | P18089 | 3/20 | 0.97 |
| ▸ | ADRA2C | P18825 | 3/20 | 0.97 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.97 |
| ▸ | HTR2A | P28223 | 3/20 | 0.97 |
| ▸ | HTR2C | P28335 | 3/20 | 0.97 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.97 |
| ▸ | MC3R | P41968 | 3/20 | 0.97 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dothiepin SCHEMBL29400117 | 1.00 | HRH1 (0.97) | HRH1ALDH1A1SLC6A2KCNH2HTR2B | |
| Dothiepin SCHEMBL3409482 | 1.00 | HRH1 (0.97) | HRH1ALDH1A1SLC6A2KCNH2HTR2B | |
| Dothiepin SCHEMBL35427 | 1.00 | HRH1 (0.97) | HRH1ALDH1A1SLC6A2KCNH2HTR2B | |
| Dothiepin SCHEMBL35426 | 1.00 | HRH1 (0.97) | HRH1ALDH1A1SLC6A2KCNH2HTR2B | |
| Dothiepin SCHEMBL34483 | 0.99 | HRH1 (1.00) | HRH1ALDH1A1SLC6A2KCNH2HTR2B | |
| Dothiepin SCHEMBL29369112 | 0.99 | HRH1 (1.00) | HRH1ALDH1A1SLC6A2KCNH2HTR2B | |
| Dothiepin SCHEMBL684145 | 0.99 | HRH1 (1.00) | HRH1ALDH1A1SLC6A2KCNH2HTR2B | |
| Dothiepin SCHEMBL3374653 | 0.99 | HRH1 (1.00) | HRH1ALDH1A1SLC6A2KCNH2HTR2B | |
| Dothiepin SCHEMBL34482 | 0.99 | HRH1 (1.00) | HRH1ALDH1A1SLC6A2KCNH2HTR2B | |
| Dothiepin SCHEMBL15795798 | 0.88 | HTR2B (0.80) | HRH1ALDH1A1SLC6A2KCNH2HTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 329 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110496178-A | A kind of dosulepin machining process | HUAYI PHARMACEUTICAL ANHUI CO LTD | 2019-11-26 | — | — | CN | claimed |
| CN-108714144-A | A kind of dosulepin piece and preparation method thereof | 华益药业科技(安徽)有限公司 | 2018-10-30 | — | — | CN | claimed |
| EP-1648430-A4 | TREATMENT OF PREMATURE EJACULATION | WORLDWIDE PE PATENT HOLDCO PTY (AU) | 2009-01-14 | — | — | EP | claimed |
| EP-1976519-A2 | CYTISINE AND ACETYLCHOLINE ANALOGS AND METHODS OF TREATING MOOD DISORDERS | Yale University (US) | 2008-10-08 | — | — | EP | claimed |
| WO-2008112297-A2 | METHODS OF TREATING CANCER BY INTERFERING WITH IGF-I RECEPTOR SIGNALING | YALE UNIVERSITY (US) | 2008-09-18 | — | — | WO | claimed |
| US-20080021411-A1 | Lipid Emulsions in the Treatment of Systemic Poisoning | RESQ PHARMA, INC. | 2008-01-24 | — | — | US | claimed |
| US-20080003275-A1 | Treatment of Premature Ejaculation | WORLDWIDE PE PATENT HOLDCO PTY LTD. (US) | 2008-01-03 | — | — | US | claimed |
| WO-2007128133-A1 | HAIR SEQUESTERED TRACER FOR PROSTHESIS LEAK DETECTION | HADDON DAVID JAMES (CA) | 2007-11-15 | — | — | WO | claimed |
| WO-2007100430-A2 | CYTISINE AND ACETYLCHOLINE ANALOGS AND METHODS OF TREATING MOOD DISORDERS | YALE UNIVERSITY (US) | 2007-09-07 | — | — | WO | claimed |
| EP-1273301-B1 | Pharmaceutical preparations based on active ingredients susceptible to illicit administration | ALTERGON SA (CH) | 2006-09-06 | — | — | EP | claimed |
| EP-1648430-A1 | TREATMENT OF PREMATURE EJACULATION | Worldwide PE Patent Holdco Pty Ltd (AU) | 2006-04-26 | — | — | EP | claimed |
| WO-2005004855-A1 | TREATMENT OF PREMATURE EJACULATION | WORLDWIDE PE PATENT HOLDCO PTY LTD (AU) | 2005-01-20 | — | — | WO | claimed |
| EP-1273301-A2 | Pharmaceutical preparations based on active ingredients susceptible to illicit administration | ALTERGON S.A. (CH) | 2003-01-08 | — | — | EP | claimed |
| EP-4114275-B1 | SYSTEMS AND METHODS FOR FLUID SAMPLE COLLECTION AND TESTING | Marshall Venture Partners LLC (US) | 2025-07-30 | — | — | EP | disclosed |
| US-12239638-B2 | Crystalline form of a 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compound | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2025-03-04 | — | — | US | disclosed |
| US-20240316024-A1 | 4-[2-(2-FLUOROPHENOXYMETHYL)PHENYL]PIPERIDINE COMPOUNDS | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2024-09-26 | — | — | US | disclosed |
| US-5795909-A | ANTICARCINOGENIC AND ANTITUMOR AGENTS; BREAST, COLON, OVARIANCANCERS | NEUROMEDICA, INC. (US) | 1998-08-18 | — | — | US | disclosed |
| US-5780051-A | Methods and articles of manufacture for nicotine cessation and monitoring nicotine use | DYNAGEN, INC. (US) | 1998-07-14 | — | — | US | disclosed |
| US-5760016-A | Use of mono-3,6-anhydrocyclodextrins for solubilizing a hydrophobic compound and for controlling the purity of an enantiomer and process for the preparation of these cyclodextrins | COMMISSARIAT A L'ENERGIE ATOMIQUE (FR) | 1998-06-02 | — | — | US | disclosed |
| WO-1997044063-A2 | DHA-PHARMACEUTICAL AGENT CONJUGATES | NEUROMEDICA, INC. (US) | 1997-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12239638-B2 | Crystalline form of a 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compound | REN, PKD2, UACA | SLC6A2 1314/4885SLC6A4 354/4885HRH1 1614/4885 |
| US-20240316024-A1 | 4-[2-(2-FLUOROPHENOXYMETHYL)PHENYL]PIPERIDINE COMPOUNDS | SLC6A2, SLC6A4, HTR6 | SLC6A2 1/4885SLC6A4 2/4885HRH1 185/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.